A new, simple, and rapid high-performance thin-layer chromatographic method has been established for quantitative analysis of risperidone. Chromatography was performed on silica gel 60 F254 plates with methanol-ethyl acetate 8.0:2.0 (v/v) as mobile phase. Risperidone was quantified by densitometric analysis at 285 nm. The method gave compact bands for the drug (RF 0.34 ± 0.01). Linear regression analysis of calibration data revealed a good linear relationship (r2 = 0.9996) between response and amount of risperidone in the range 100–600 ng per band. The method was validated for precision, recovery, repeatability, linearity, specificity, and robustness in accordance with ICH guidelines. The minimum detectable amount was 22.44 ng per band and the limit of quantification was 68.01 ng per band. Statistical analysis of the results showed the method enabled precise, accurate, reproducible, and selective analysis of risperidone. The method was successfully used for estimation of the equilibrium solubility of risperidone, and for quantification of risperidone as the bulk drug in a commercially available preparation, in in-house-developed mucoadhesive microemulsion formulations, and in solution.
[1]. J. Carman J. Peuskens A. Vangeneugden 1995 Int. Clin. Psychopharmacol. 10 207–213.
[2]. H. He J.S. Richardson 1995 Int. Clin. Psychopharmacol. 10 19–30.
[3]. A.A. Megens F.H. Awouters A. Schotte T.F. Meert C. Dugovic C.J. Niemegeers J.E. Leysen 1993 Psychopharmacology 114 9–23.
[4]. C.R. Behl H.K. Pimplaskar A.P. Sileno J. De Meireles V.D. Romeo 1998 Adv. Drug Del. Rev. 29 89–116.
[5]. L.G. Candace G.M. Pollock 2005 J. Pharm. Sci. 94 187–195.
[6]. H.S. Chow Z. Chen G.T. Matsuura 1999 J. Pharm. Sci. 88 754–758.
[7]. T.K. Vyas A.K. Babber R.K. Sharma S. Singh A. Misra 2006 J. Pharm. Sci. 95 570–580.
[8]. L. Li I. Nandi K.H. Kim 2002 Int. J. Pharm. 237 77–85.
[9]. S. Mathison R. Nagilla U.B. Kompella 1998 J. Drug Target 56 415–441.
[10]. R. Pietrowky A. Thieman W. Kern H.L. Fehm J. Bern 1996 Psychoneuroendocrinology 21 559–572.
[11]. Z. Qizhi X. Jiang W. Xiang W. Lu L. Su Z. Shi 2004 Int. J. Pharm. 275 85–96.
[12]. M.J. Lawrence G.D. Rees 2000 Adv. Drug Deliv. Rev. 45 89–121.
[13]. K.E. Goeringa I.M. McIntyre O.H. Drunmer 2003 J. Anal. Toxicol. 27 30–35.
[14]. D. Thieme H. Saches 2003 J. Anal. Chim. Acta 492 171–186.
[15]. A. Pelander I. Ojanpera S. Laks I. Rasanen E. Vuori 2003 J. Anal. Chem. 75 5710–5718.
[16]. A.E. Balant-Gorgia M. Gex-Fabry C. Genet L.P. Balant 1999 J. Ther. Drug Monit. 21 105–115.
[17]. M. Aravagiri S.R. Marder T. Van-Putten K.K. Midha 1993 J. Pharm. Sci. 82 447–449.
[18]. A.C. Springfield E. Bodiford 1996 J. Anal. Toxicol. 20 202–203.
[19]. G. Casamenti R. Mandrioli C. Sabbioni F. Bugamelli V. Volterra M.A. Raggi 2000 J. Chromatogr. Relat. Technol. 23 1039–1059.
[20]. M.A. Raggi G. Casamenti R. Mandrioli C. Sabbioni V. Volterra 2000 J. Pharm. Biomed. Anal. 23 161–167.
[21]. M. Andersson U.K. Hultin A. Sokolowski 1998 Chromatographia 48 770–776.
[22]. R. Woestenborghs W. Lorreyne F. Van Rompaey J. Heykants 1992 J. Chromatogr. Biomed. Appl. 121 223–230.
[23]. J.P. Le-Moing S. Edouard J.C. Levron 1993 J. Chromatogr. Biomed. Appl. 125 333–339.
[24]. O.V. Olesen K. Linnet 1997 J. Chromatogr. Biomed. Appl. 698 209–216.
[25]. M.C. Price D.W. Hoffman 1997 J. Ther. Drug Monit. 19 333–337.
[26]. M. Aravagiri S.R. Marder D. Wirshing W. C. Wirshing 1998 Pharmacopsychiatry 31 102–109.
[27]. T. Nagasaki T. Ohkubo K. Sugawara N. Yasui H. Furukori S. Kaneko 1999 J. Pharm. Biomed. Anal. 19 595–601.
[28]. H. Xiao J. Yang S.N. Zhang X.B. Zhang 1999 Sepu 17 395–396.
[29]. A. Avenoso G. Facciola M. Salemi E. Spina 2000 J. Chromatogr. B Biomed. Sci. Appl. 746 173–181.
[30]. D.S. Schatz A. Saria 2000 Pharmacology 60 51–56.
[31]. C. Frahnert M.L. Rao K. Grasmaeder 2003 J. Chromatogr. B Anal, Technol. Biomed. Life Sci. 794 35–47.
[32]. K. Titier S. Bouchet F. Pehourcq N. Moore M. Molimard 2003 J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 799 179–183.
[33]. K. Titier E. Deridet E. Cardone A. Abouelfath N. Moore 2002 J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 772 373–378.
[34]. Y.L. Shen H.L. Wu W.K. Ko S.M. Wu 2002 J. Anal. Chim. Acta 460 201–208.
[35]. A. Lierena R. Berecz P. Dorado C. Sanz-de-la-Garza M.J. Norberto M. Caceres J.R. Gutierrez 2003 J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 783 213–219.
[36]. B.M.M. Remmerie L.L.A. Sipes R. De-Vries J. De-Jong A.M. Schothuis E.W.J. Hooi Jschuur N.C. Van-de-Merbel 2003 J. Chromatogr. B Anal. Technol., Biomed. Life Sci. 783 461–472.
[37]. M. Aravagiri S.R. Marder 2000 J. Mass Spectrom. 35 718–724.
[38]. S. McClean E.J. O'Kane W.F. Smyth 2000 J. Chromatogr B Biomed. Appl. 740 141–157.
[39]. M. Gergov I. Ojanpera E. Vuori 2003 J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 795 41–53.
[40]. A. Pelander I. Ojanpera J. Sistonen I. Rasanen E. Vuori 2003 J. Anal., Toxicol. 27 226–232.
[41]. J. Schuberth 1996 J. Anal. Chem. 68 1317–1320.
[42]. H.H. Maurer T. Kraemer C. Kratzsch F.T. Peters A.A. Weber 2002 J. Ther. Drug Monit. 24 117–124.
[43]. V. Pucci M.A. Raggi E. Kenndler 2000 J. Liq. Chromatogr. Relat. Technol. 23 25–34.
[44]. V. Pucci M.A. Raggi E. Kenndler 2000 J. Chromatogr. B Biomed. Appl. 728 263–271.
[45]. X.F. Zhu S. Thiam B.C. Valle I.M. Warner 2002 J. Anal. Chem. 74 5405–5409.
[46]. Z.A. El-Sherif B. El-Zeany O.M. El-Houssini 2005 J. Pharm. Biomed. Anal. 36 975–981.
[47]. R.B. Patel A.B. Patel M.R. Patel M.B. Shankar K.K. Bhatt 2009 Anal. Lett. 42 1588–1602.
[48]. V.B. Borhade H.A. Nair D.D. Hegde C.R. Barhate 2009 Drug Dev. Ind. Pharm. 35 440–448.
[49]. R.B. Patel M.R. Patel M.B. Shankar K.K. Bhatt 2008 J. AOAC Int. 91 750–755.
[50]. Validation of Analytical Procedure: Methodology Q2 (R1) International Conference on Harmonization (ICH), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland, 1996.